Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The COPD pipeline

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: The COPD pipeline.

References

  1. Kardos, P. et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 144–149 (2007).

    CAS  Article  Google Scholar 

  2. Maltais, F. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients (Abstract 5557). Eur. Respir. J. 36 (Suppl. 54), 1014s (2010).

    Google Scholar 

  3. Franciosi, L. G. et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from our four clinical trials. Lancet Respir. Med. 9, 714–727 (2013).

    Article  Google Scholar 

  4. GBI Research. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019. GBIHC299MR (2013).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yasser Mushtaq.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mushtaq, Y. The COPD pipeline. Nat Rev Drug Discov 13, 253–254 (2014). https://doi.org/10.1038/nrd4254

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4254

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing